Influenza virus split vaccine not checked
Shanghai Institute Of Biological Products
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Influenza virus split vaccine, with a specification of 0.7mL/bottle, containing 60 μ g of hemagglutinin from H1N1, H3N2, and B influenza virus strains each Control: Influenza virus split vaccine.”In the company’s words, NCT07327398 on ClinicalTrials.gov
- Tested for
- Influenza (2 trials)
- Main trialPhase 2
- “To evaluate the immunogenicity of administering one dose of influenza virus split vaccine (0.7mL/dose) to individuals aged 60 and above.”In the company’s words, NCT07327398 on ClinicalTrials.gov
Other drugs for Influenza
- MRNA-1018-H5Moderna · Phase 3
- Baloxavir MarboxilRoche · Phase 3
- BRC-201Boryung Biopharma Co., Ltd. · Phase 3
- Dipyrone monohydrateBrainfarma Industria Química e Farmacêutica S/A · Phase 3
- CD388Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · Phase 3
- MRNA Seasonal Flu vaccineGSK · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | 30 Sep 2026 | Phase Ⅱ Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above | |
| Phase 1Recruiting | 31 Aug 2026 | A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026